ArticleHPB : the official journal of the International Hepato Pancreato Biliary Association2022
Chinese expert recommendations on management of hepatocellular carcinoma during COVID-19 pandemic: a nationwide multicenter survey.
Open access · hybridAbstract readMulticenter Study
In one paragraph
Article in HPB : the official journal of the International Hepato Pancreato Biliary Association, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 35% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.
- Effect of coronavirus disease 2019 on diagnosis and treatment of hepatocellular carcinoma: a systematic review.Exploration of targeted anti-tumor therapy · 2023Pooled it
- Use of Virtual Oncology in Hepatopancreatobiliary Cancers: A Scoping Review.Annals of surgical oncology · 2026Article
- Article
- Screening, Surveillance, and Management of Hepatocellular Carcinoma During the COVID-19 Pandemic: a Narrative Review.Journal of gastrointestinal cancer · 2023Review
- Impact of SARS-CoV-2 Pandemic on the Management of Patients with Hepatocellular Carcinoma.Journal of clinical medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
72 authors at 20 institutions in 1 country.
Hong ZhaoDepartment of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Key Laboratory of Gene Editing Screening and R&D of Digestive System Tumor Drugs, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Aiping ZhouDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Jianguo ZhouDepartment of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Xinyu BiDepartment of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Key Laboratory of Gene Editing Screening and R&D of Digestive System Tumor Drugs, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Shida YanDepartment of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Jing JinDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Wenqiang WeiOffice for Cancer Registry, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Muxing LiDepartment of General Surgery, Peking University Third Hospital, Beijing, China.
Caifeng GongDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Qichen ChenDepartment of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Zhiwen LuoDepartment of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Ning LiDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Rui MaoDepartment of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Xiao ChenDepartment of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Bo ChenDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Rongshou ZhengOffice for Cancer Registry, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Jianjun ZhaoDepartment of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Yue HanDepartment of Interventional Therapy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Zhiyu LiDepartment of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Xu CheDepartment of Pancreatic and Gastric Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Department of Hepatobiliary and Pancreatic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China.
Yuan TangDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Yongkun SunDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Zhen HuangDepartment of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Yefan ZhangDepartment of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Xiaoying WangDepartment of Liver Surgery & Liver Transplant Center, Zhongshan Hospital, Fudan University, Shanghai, China.
Yubao ZhangDepartment of Hepatobiliary and Pancreatic Surgery, Harbin Medical University Cancer Hospital, Harbin, China.
Zhenhui LuDepartments of Hepatobiliary Surgery, General Hospital of Ningxia Medical University, Yinchuan, China.
Xiaowei DangDepartment of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Tianqiang SongDepartment of Hepatobiliary Cancer, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China.
Chang LiuDepartment of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Ping YueDepartment of General Surgery, The First Hospital of Lanzhou University, Lanzhou, China.
Dong YanDepartment of Hepatopancreatobiliary Surgery, The Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, China.
Aimin YueDepartment of Surgical Oncology, Xinxiang Central Hospital, Xinxiang, China.
Rui ZhangDepartment of Colorectal Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, China.
Suxia LuoHenan Cancer Hospital, Zhengzhou, China.
Jing TanYan'an Affiliated Hospital of Kunming Medical University, Kunming, China.
Xuewen ZhangDepartment of Hepatobiliary and Pancreatic Surgery, The Second Hospital of Jilin University, Changchun, China.
Xueli BaiDepartment of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhejiang University School of Medicine, Zhejiang Clinical Research Cneter of Hepatobiliary and Pancreatic Diseases, Hangzhou, China.
Xuejun ZhangDepartment of Intervention, Inner Mongolia People's Hospital, Hohhot, China.
Mingyan HeDepartment of the Third Abdominal Surgery, Gansu Provincial Cancer Hospital, Lanzhou, China.
Yujun XieDepartment of Intervention Ultrasound, Ningxia People's Hospital, Yinchuan, China.
Wenling WangDepartment of Oncology, The Affiliated Cancer Hospital of Guizhou Medical University, Guiyang, China.
Po YangDepartment of Interventional & Vascular Therapy, The Fourth Hospital of Harbin Medical University, Harbin, China.
Yijun YangDepartment of Hepatobiliary Surgery, Haikou Municipal Hospital, Haikou, China.
Yamin ZhangDepartment of Hepatobiliary Surgery, Tianjin First Center Hospital, Tianjin, China.
Qingdong LiVascular and Interventional Department, Chongqing University Cancer Hospital, Chongqing, China.
Tao PengDepartment of Hepatobiliary Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Zusen WangDepartment of Hepatobiliary Surgery, The Affiliated Hospital of Qingdao University, Qingdao, China.
Yajin ChenDepartment of Hepatobiliary Surgery, Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, China.
Changzhen ShangDepartment of Hepatobiliary Surgery, Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, China.
Yingjian LiangDepartment of General Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Bixiang ZhangHepatic Surgery Center, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China.
Feng ZhangDepartment of Hepatobiliary and Pancreatic Surgery, Hubei Cancer Hospital, Wuhan, China.
Liming WangDepartment of Hepatobiliary and Pancreatic Surgery, The Second Hospital of Dalian Medical University, Dalian, China.
Duo LiDepartment of Hepatopancreatobiliary Surgery, Hainan Cancer Hospital, Haikou, China.
Bin LiuDepartment of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Kunming Medical University, Kumming, China.
Xiaofeng ZhuDepartment of Transplantation, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Qinggang HuDepartment of Hepatobiliary Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Minshan ChenDepartment of Hepatobiliary Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China.
Dianrong XiuDepartment of General Surgery, Peking University Third Hospital, Beijing, China.
Feng XiaInstitute of Hepatobiliary Surgery, Southwest Hospital, Army Medical University, Chongqing, China.
Yanqiao ZhangDepartment of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Yong ZengDepartment of Liver Surgery, West China Hospital, Sichuan University, Chengdu, China.
Yilei MaoDepartment of Liver Surgery, Peking Union Medical College Hospital, Peking Union Medical College, Beijing, China.
Xun LiDepartment of General Surgery, The First Hospital of Lanzhou University, Lanzhou, China.
Yi BaTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University, Tianjin, China.
Tingbo LiangDepartment of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhejiang University School of Medicine, Zhejiang Clinical Research Cneter of Hepatobiliary and Pancreatic Diseases, Hangzhou, China.
Feng ShenDepartment of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, The Second Military Medical University, Shanghai, China.
Lianxin LiuDepartment of Hepatobiliary Surgery, The First Affiliated Hospital of University of Science and Technology of China, China.
Xiujun CaiSir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Jian ZhouDepartment of Liver Surgery & Liver Transplant Center, Zhongshan Hospital, Fudan University, Shanghai, China.
Jianqiang CaiDepartment of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Key Laboratory of Gene Editing Screening and R&D of Digestive System Tumor Drugs, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. Electronic address: caijianqiang@cicams.ac.cn.
Chinese Academy of Medical Sciences & Peking Union Medical College · CNFirst Affiliated Hospital Zhejiang University · CNFirst Hospital of Lanzhou University · CNFudan University · CNPeking University Third Hospital · CNSun Yat-sen University · CNThird Affiliated Hospital of Harbin Medical University · CNTianjin Medical University Cancer Institute and Hospital · CNArmy Medical University · CNChongqing Cancer Hospital · CNFirst Affiliated Hospital of GuangXi Medical University · CNFirst Affiliated Hospital of Harbin Medical University · CNFirst Affiliated Hospital of Kunming Medical University · CNFirst Affiliated Hospital of Xi'an Jiaotong University · CNFirst Affiliated Hospital of Zhengzhou University · CNFourth Affiliated Hospital of Harbin Medical University · CNGansu Provincial Hospital · CNGuiyang Medical University · CNHaikou City People's Hospital · CNHainan Medical College Hospital · CN
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to investigate the work status of clinicians in China and their management strategy alteration for patients with hepatocellular carcinoma (HCC) during the COVID-19 pandemic.
methodsA nationwide online questionnaire survey was conducted in 42 class-A tertiary hospitals across China. Experienced clinicians of HCC-related specialties responded with their work status and management suggestions for HCC patients during the pandemic.
results716 doctors responded effectively with a response rate of 60.1%, and 664 were included in the final analysis. Overall, 51.4% (341/664) of clinicians reported more than a 60% reduction of the regular workload and surgeons declared the highest proportion of workload reduction. 92.5% (614/664) of the respondents have been using online medical consultation to substitute for the "face-to-face" visits. Adaptive adjustment for the treatment strategy for HCC was made, including the recommendations of noninvasive and minimally invasive treatments such as transcatheter arterial chemoembolization for early and intermediate stage. Targeted therapy has been the mainstay for advanced stage and also as a bridge therapy for resectable HCC. DISCUSSION: During the COVID-19 pandemic, online medical consultation is recommended to avoid social contact. Targeted therapy as a bridge therapy is recommended for resectable HCC considering the possibility of delayed surgery.
Indexed as
Carcinoma, HepatocellularChemoembolization, TherapeuticCOVID-19Liver NeoplasmsHumansPandemicsSARS-CoV-2Surveys and Questionnaires
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.